Takeda Pharmaceuticals: Global Homepage

This new building produces more energy than it uses

We exist to create better health for people and a brighter future for the world. While the science and technology we advance are constantly evolving, our ambition remains. We move science forward, so we can transform more lives.

Recent News

Takeda Provides Update on EXKIVITY® (mobocertinib)

October 2, 2023

Takeda Announces Amendment of Compensation Recoupment Policy

October 2, 2023

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

September 27, 2023

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

September 25, 2023

View All

How we create positive impact through our values

Our 2023 Annual Integrated Report is now available.

LEARN MORE

Better Health, Brighter Future

Join Us

Work with globally diverse colleagues who are committed to bringing Better Health to people and a Brighter Future to the world.

FIND OUT MORE

Investors

Discover our balanced, diverse portfolio and strategy for sustainable, patient-centered and resilient growth.

FIND OUT MORE

R&D

Fueled by our inherent curiosity, we translate science into highly innovative, life-transforming medicines.

FIND OUT MORE

Our Areas of Focus

Gastrointestinal and Inflammation

Understanding and addressing life-limiting gastrointestinal and inflammatory diseases

Rare Diseases

Working to transform treatments in immunology, hematology, metabolic and lysosomal storage disorders

Plasma-Derived Therapies

Improving the lives of patients with rare and complex chronic diseases through innovation in plasma

Oncology

Aspiring to cure cancer, with inspiration from patients and innovation from everywhere

Neuroscience

Driving medical innovation for patients with neurological diseases

Vaccines

Addressing unmet global health needs through vaccine development against infectious diseases

Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet

Sign up

Takeda Pharmaceuticals: Global Homepage

This new building produces more energy than it uses

Recent News

Takeda Provides Update on EXKIVITY® (mobocertinib)

Takeda Announces Amendment of Compensation Recoupment Policy

U.S. FDA Approves Subcutaneous Administration of Takeda's ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis

Takeda Announces Approval of CUVITRU Subcutaneous Immunoglobulin in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia

How we create positive impact through our values

Better Health, Brighter Future

Join Us

Investors

R&D

Our Areas of Focus

Gastrointestinal and Inflammation

Rare Diseases

Plasma-Derived Therapies

Oncology

Neuroscience

Vaccines

Sign up for investors newsletter